Composition for diagnosis or treatment of anticancer drug resistance
AssigneeJong-Baeck Lim
InventorsJong-Baeck Lim, Jae-Il Choi, Hye Won Chung
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition for diagnosing resistance to a combination of ECF (Epirubicin, Cisplatin and 5-Fluorouracil; ECF), which is used for the treatment of gastric cancer, and a diagnostic kit comprising the same. In order to solve a problem that cancer recurrence and drug resistance occur due to an increase in tumor initiating cells (TICs) after treatment with a drug belonging to the ECF family, NINJ2 may be inhibited by early detection of resistance appearance, thereby suppressing the recurrence of gastric cancer and treating resistance to the drugs.
Claims1
A method for treating anticancer drug resistance or enhancing anticancer drug sensitivity, comprising a step of administering an effective amount of an agent for reducing the expression level of a gene encoding NINJ2 (nerve injury-induced protein 2;
- Ninjurin 2) protein to a subject in need thereof, wherein the agent for reducing the expression level of the gene is any one or more selected from the group consisting of an antisense nucleotide, a short interfering RNA (siRNA), a short hairpin RNA, and ribozyme, which bind complementarily to the NINJ2 gene or a portion thereof, wherein the subject has gastric cancer and has resistance to anticancer drugs comprising epirubicin, cisplatin, and 5-fluorouracil.
Dependencies are inferred from the claim text.